Biotechnology

Revelation Biosciences

Revelation Biosciences released FY2025 Q3 earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -1.7683

Revelation Biosciences released FY2025 9 Months Earnings on November 6, 2025 (EST) with actual revenue of USD 0 and EPS of USD -15.1126

Revelation Biosciences released FY2025 Q2 earnings on August 8 (EST), actual revenue USD 0, actual EPS USD -7.01

Revelation Biosciences released FY2025 Semi-Annual earnings on August 8, 2025 (EST), with actual revenue of USD 0 and EPS of USD -13.5986

Revelation Biosciences Inc. Completes PRIME 1b Phase Clinical Trial Dosing

Revelation Biosciences Inc. Issues $4 Million in Common Stock

Revelation Biosciences released FY2025 Q1 earnings on May 8 (EST) with actual revenue of USD 0 and EPS of USD -6.3349

Revelation Biosciences Reports Smaller Net Loss in Q1 2025

Revelation Biosciences Inc. Announces New Clinical Study for Gemini Platform

Revelation Biosciences Inc announces GEMINI pre-treatment alleviates inflammation in human peripheral blood mononuclear cells

Revelation Biosciences released FY2024 Annual Earnings on March 6 (EST), actual revenue USD 0, actual EPS USD -263.0494

Revelation Biosciences released FY2024 Q4 earnings on March 6, 2025 (EST), with actual revenue of USD 0 and EPS of USD -14.9411

Revelation Biosciences released FY2024 9 Months Earnings on November 8, 2024 (EST) with actual revenue of USD 0 and EPS of USD -404.5212

Revelation Biosciences released FY2024 Q3 earnings on November 8 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -40.1483 (forecast USD --)

Revelation Biosciences released FY2024 Q2 earnings on August 9 (EST), actual revenue USD 0, actual EPS USD -246.274

Revelation Biosciences released FY2024 Semi-Annual Earnings on August 9 (EST), with actual revenue of USD 0 and EPS of USD -390.24

Revelation Biosciences released FY2024 Q1 earnings on May 10 (EST) with actual revenue of USD 0 and actual EPS of USD -118.0987

Revelation Biosciences released FY2023 Annual Earnings on March 22, 2024 (EST), with actual revenue of USD 0 and actual EPS of USD 0

Revelation Biosciences released FY2023 Q4 earnings on March 22 (EST), actual revenue USD 0, actual EPS USD 0

Revelation Biosciences released FY2023 9 Months Earnings on November 9, 2023 (EST) with actual revenue of USD 0 and EPS of USD 0

Sobr Safe

Omeros

Northann

AMC Robotics

Euda Health

Multi Ways

Dynavax Tech

Indaptus Therapeutics

Sidus Space

Kandal M Venture

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap